AptaPharma is a pharmaceutical CDMO headquartered in Pennsauken, New Jersey, providing end-to-end services from formulation development through to commercial manufacturing and product commercialisation. The company operates an 83,000-square-foot cGMP manufacturing campus and supports pharmaceutical and biotechnology companies with the development of complex drug products. Its expertise spans controlled-release solid dosage forms, oral liquids and suspensions, and softgel manufacturing.

A key element of AptaPharma’s offering is its proprietary Sugar Lipid Polymer (SLP) platform, a patented and FDA-recognised drug delivery technology designed to address formulation challenges such as poor solubility, low bioavailability, product instability and patient tolerability issues. The technology is intended to improve formulation performance while supporting enhanced stability, taste masking and reduced gastrointestinal irritation.

The company positions itself as a molecule-to-market partner, combining formulation science, manufacturing expertise and regulatory-ready infrastructure to support both emerging biotechnology companies and established pharmaceutical organisations. Its FDA-inspected facility is designed to support development programmes from early-stage formulation through commercial supply.

Key Products and Services

• Contract development and manufacturing (CDMO) services
• Pharmaceutical formulation development
• Clinical manufacturing support
• Commercial manufacturing services
• Commercialisation support
• Controlled-release solid dosage form development and manufacturing
• Oral liquid and suspension formulation and manufacturing
• Softgel development and manufacturing
• Sugar Lipid Polymer (SLP) drug delivery platform
• Solubility enhancement solutions
• Bioavailability improvement technologies
• Taste-masking technologies
• Stability enhancement solutions
• Regulatory-ready manufacturing support
• cGMP manufacturing services

AptaPharma focuses on helping pharmaceutical companies overcome complex formulation and manufacturing challenges through a combination of proprietary drug delivery technologies, formulation expertise and integrated CDMO services. By supporting programmes from development through commercialisation, the company aims to accelerate the delivery of differentiated therapies while maintaining regulatory compliance and manufacturing quality.